tonix
pharmaceuticals
enrolls
first
patient
observational
study
assess
antibody
cell
responses
virus
causes
new
york
globe
newswire
tonix
pharmaceuticals
holding
nasdaq
tnxp
tonix
company
biopharmaceutical
company
today
announced
first
patient
enrolled
observational
study
study
humoral
antibody
cellular
cell
immune
responses
volunteers
recovered
remain
asymptomatic
exposure
research
part
ongoing
broader
collaboration
tonix
southern
research
develop
conduct
animal
testing
tonix
live
replicating
attenuated
virus
vaccine
designed
protect
represents
significant
milestone
company
data
plan
collect
recovered
asymptomatic
volunteers
study
help
inform
vaccine
development
safely
provide
immune
responses
others
got
recovering
actual
infection
said
seth
lederman
president
ceo
tonix
goal
develop
vaccine
well
tolerated
produces
strong
immunity
rapidly
broadly
deployed
features
protective
immune
response
remain
unknown
since
virus
believe
cell
responses
particular
helper
type
responses
play
important
dominant
role
protecting
serious
illness
study
study
observational
sample
collection
study
designed
collect
blood
nasopharyngeal
np
swabs
individuals
previously
infected
intimately
exposed
persons
confirmed
infected
order
analyze
antibody
titers
responses
specific
proteins
detect
rna
may
persistent
nasopharynx
time
sampling
individuals
viral
rna
detected
initial
sampling
repeat
blood
np
swab
samples
may
collected
examine
temporal
virus
immune
response
dynamics
addition
blood
collected
dna
extraction
exome
sequencing
order
assess
whether
host
genetic
factors
might
influence
humoral
cellular
responses
viral
persistence
identified
live
modified
horsepox
virus
vaccine
percutaneous
administration
designed
express
spike
protein
virus
causes
elicit
predominant
cell
response
horsepox
vaccinia
closely
related
orthopoxviruses
believed
share
common
ancestor
live
replicating
orthopoxviruses
like
vaccinia
horsepox
engineered
express
foreign
genes
explored
platforms
vaccine
development
possess
large
packaging
capacity
exogenous
dna
inserts
precise
control
exogenous
gene
insert
expression
lack
persistence
genomic
integration
host
strong
immunogenicity
vaccine
ability
rapidly
generate
vector
insert
constructs
readily
manufacturable
scale
ability
provide
direct
antigen
presentation
relative
vaccinia
horsepox
substantially
decreased
virulence
vaccines
designed
single
dose
vaccines
manufactured
conventional
cell
culturing
systems
potential
mass
scale
production
rs
et
al
plos
one
southern
research
founded
southern
research
sr
independent
c
nonprofit
scientific
research
organization
scientists
engineers
working
across
three
divisions
drug
discovery
drug
development
engineering
sr
supported
pharmaceutical
biotechnology
defense
aerospace
environmental
energy
industries
sr
works
behalf
national
institutes
health
department
defense
department
energy
nasa
major
aerospace
firms
utility
companies
external
academic
industry
government
agencies
sr
pursues
entrepreneurial
collaborative
initiatives
develop
maintain
pipeline
intellectual
property
innovative
technologies
positively
impact
problems
sr
numerous
ongoing
drug
discovery
programs
encompass
drug
candidates
combat
various
forms
cancer
amyotrophic
lateral
sclerosis
als
alzheimer
schizophrenia
opioid
use
disorder
human
immunodeficiency
virus
diabetes
kidney
disease
parkinson
tuberculosis
influenza
others
sr
strong
history
includes
years
successful
collaborations
solve
complex
problems
led
discovery
seven
cancer
number
rivaling
research
institute
furthermore
experts
sr
assist
challenging
landscapes
drug
design
development
technologies
market
viability
sr
headquartered
birmingham
alabama
additional
laboratories
offices
frederick
maryland
information
sr
found
https
tonix
pharmaceuticals
holding
tonix
biopharmaceutical
company
focused
discovering
licensing
acquiring
developing
small
molecules
biologics
treat
prevent
human
disease
alleviate
suffering
tonix
portfolio
primarily
composed
central
nervous
system
cns
immunology
product
candidates
immunology
portfolio
includes
vaccines
prevent
infectious
diseases
biologics
address
immunosuppression
cancer
autoimmune
diseases
cns
portfolio
includes
small
molecules
biologics
treat
pain
neurologic
psychiatric
addiction
conditions
tonix
lead
vaccine
candidate
live
replicating
vaccine
based
horsepox
viral
vector
platform
protect
primarily
eliciting
cell
response
tonix
expects
data
animal
studies
fourth
quarter
year
live
horsepox
virus
vaccine
percutaneous
administration
development
protect
smallpox
monkeypox
serves
vector
platform
based
tonix
also
developing
live
replicating
vaccine
candidates
prevention
using
bovine
parainfluenza
vector
tonix
lead
cns
candidate
sl
phase
development
management
fibromyalgia
company
expects
results
unblinded
interim
analysis
september
topline
data
fourth
quarter
tonix
also
currently
enrolling
patients
second
phase
study
management
fibromyalgia
using
sl
results
expected
second
half
sl
also
development
agitation
alzheimer
disease
alcohol
use
disorder
aud
agitation
alzheimer
disease
program
phase
ready
fda
fast
track
designation
aud
program
also
phase
ready
tonix
programs
treating
addiction
conditions
also
include
cocaine
esterase
mg
solution
phase
development
treatment
cocaine
intoxication
fda
breakthrough
therapy
designation
cr
tianeptine
oxalate
tablets
another
cns
program
currently
phase
development
daytime
treatment
depression
intranasal
oxytocin
development
treatment
migraine
pain
tonix
preclinical
pipeline
includes
triple
reuptake
inhibitor
new
molecular
entity
developed
treatment
ptsd
monoclonal
antibody
developed
prevent
treat
organ
transplant
rejection
autoimmune
conditions
biologic
developed
treat
gastric
pancreatic
cancers
investigational
new
biologics
approved
indication
sl
cr
investigational
new
drugs
approved
indication
press
release
information
tonix
found
forward
looking
statements
certain
statements
press
release
within
meaning
private
securities
litigation
reform
act
statements
may
identified
use
words
anticipate
believe
forecast
estimate
expect
intend
among
others
statements
based
tonix
current
expectations
actual
results
could
differ
materially
number
factors
could
cause
actual
events
differ
materially
indicated
statements
factors
include
limited
risks
related
failure
obtain
fda
clearances
approvals
noncompliance
fda
regulations
delays
uncertainties
caused
global
pandemic
risks
related
timing
progress
clinical
development
product
candidates
need
additional
financing
uncertainties
patent
protection
litigation
uncertainties
government
third
party
payor
reimbursement
limited
research
development
efforts
dependence
upon
third
parties
substantial
competition
pharmaceutical
development
significant
risks
development
regulatory
approval
commercialization
new
products
tonix
undertake
obligation
update
revise
statement
investors
read
risk
factors
set
forth
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
march
periodic
reports
filed
sec
date
thereof
tonix
statements
expressly
qualified
risk
factors
cautionary
statements
information
set
forth
herein
speaks
date
thereof
jessica
morris
corporate
tonix
pharmaceuticals
travis
kruse
media
russo
partners
peter
vozzo
investors
westwicke
